197 related articles for article (PubMed ID: 11353628)
1. Resistance studies with daptomycin.
Silverman JA; Oliver N; Andrew T; Li T
Antimicrob Agents Chemother; 2001 Jun; 45(6):1799-802. PubMed ID: 11353628
[TBL] [Abstract][Full Text] [Related]
2. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
4. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin.
Entenza JM; Giddey M; Vouillamoz J; Moreillon P
Int J Antimicrob Agents; 2010 May; 35(5):451-6. PubMed ID: 20185277
[TBL] [Abstract][Full Text] [Related]
5. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
7. Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar.
Johnson AP; Mushtaq S; Warner M; Livermore DM
J Antimicrob Chemother; 2004 May; 53(5):860-2. PubMed ID: 15056637
[TBL] [Abstract][Full Text] [Related]
8. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of daptomycin resistance in Staphylococcus aureus.
Kaatz GW; Lundstrom TS; Seo SM
Int J Antimicrob Agents; 2006 Oct; 28(4):280-7. PubMed ID: 16963232
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey.
Arslan H; Azap OK; Ergin F; Karaman SO; Oruç E
Int J Antimicrob Agents; 2004 Jun; 23(6):642-3. PubMed ID: 15194140
[No Abstract] [Full Text] [Related]
11. Daptomycin in vitro susceptibility in European Gram-positive clinical isolates.
Fluit AC; Schmitz FJ; Verhoef J; Milatovic D
Int J Antimicrob Agents; 2004 Jul; 24(1):59-66. PubMed ID: 15225863
[TBL] [Abstract][Full Text] [Related]
12. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
Johnson AP; Mushtaq S; Warner M; Livermore DM
Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
[TBL] [Abstract][Full Text] [Related]
13. Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype.
Begic D; von Eiff C; Tsuji BT
J Antimicrob Chemother; 2009 May; 63(5):977-81. PubMed ID: 19304733
[TBL] [Abstract][Full Text] [Related]
14. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species.
Richter SS; Kealey DE; Murray CT; Heilmann KP; Coffman SL; Doern GV
J Antimicrob Chemother; 2003 Jul; 52(1):123-7. PubMed ID: 12805265
[TBL] [Abstract][Full Text] [Related]
15. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
[TBL] [Abstract][Full Text] [Related]
16. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
Camargo IL; Neoh HM; Cui L; Hiramatsu K
Antimicrob Agents Chemother; 2008 Dec; 52(12):4289-99. PubMed ID: 18824611
[TBL] [Abstract][Full Text] [Related]
17. Turbidimetric response of Staphylococcus aureus and Enterococcus faecalis to daptomycin.
Wale MC; Wale LJ; Greenwood D
Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):809-12. PubMed ID: 2850913
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of daptomycin against Staphylococcus aureus and vancomycin-resistant Enterococcus faecium isolates associated with skin and soft tissue infections: first results from India.
Dhawan B; Gadepalli R; Kapil A
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):196-8. PubMed ID: 19748433
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).
Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):158-62. PubMed ID: 19748426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
